These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20865737)

  • 21. Chinese herbal medicine for epidermal growth factor receptor inhibitor-induced skin rash in patients with malignancy: An updated meta-analysis of 23 randomized controlled trials.
    Chen ZQ; Li ZY; Yang CZ; Lin RT; Lin LZ; Sun LL
    Complement Ther Med; 2019 Dec; 47():102167. PubMed ID: 31780021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash.
    Vaubel J; Livingstone E; Schadendorf D; Zimmer L
    J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1685-9. PubMed ID: 24422792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
    Orditura M; De Vita F; Galizia G; Lieto E; Vecchione L; Vitiello F; Martinelli E; Ciardiello F
    Oncol Rep; 2009 Apr; 21(4):1023-8. PubMed ID: 19288004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
    Agirgol S; Çaytemel C; Pilanci KN
    Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Zaborowska-Szmit M; Kowalski DM; Piórek A; Krzakowski M; Szmit S
    Pharmacol Rep; 2016 Dec; 68(6):1140-1148. PubMed ID: 27588390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
    Jatoi A; Green EM; Rowland KM; Sargent DJ; Alberts SR
    Oncology; 2009; 77(2):120-3. PubMed ID: 19622902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Xerosis and pruritus as major EGFRI-associated adverse events.
    Clabbers JMK; Boers-Doets CB; Gelderblom H; Stijnen T; Lacouture ME; van der Hoeven KJM; Kaptein AA
    Support Care Cancer; 2016 Feb; 24(2):513-521. PubMed ID: 26111953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.
    McKibbin T; Zhao W; Tagen M; Daw NC; Furman WL; McGregor LM; Geyer JR; Allen JW; Stewart CF
    Eur J Cancer; 2010 Jul; 46(11):2045-51. PubMed ID: 20621735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial.
    Brøndum L; Alsner J; Sørensen BS; Maare C; Johansen J; Primdahl H; Evensen JF; Kristensen CA; Andersen LJ; Overgaard J; Eriksen JG
    Acta Oncol; 2018 Sep; 57(9):1159-1164. PubMed ID: 29771169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections.
    Braden RL; Anadkat MJ
    Support Care Cancer; 2016 Sep; 24(9):3943-50. PubMed ID: 27117557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).
    Jatoi A; Dakhil SR; Sloan JA; Kugler JW; Rowland KM; Schaefer PL; Novotny PJ; Wender DB; Gross HM; Loprinzi CL;
    Support Care Cancer; 2011 Oct; 19(10):1601-7. PubMed ID: 20820817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Side effects of targeted therapies: rash.
    Eaby-Sandy B; Lynch K
    Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
    Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Steffens M; Scholl C; Hichert V; Seufferlein T; Stingl JC
    Eur J Cancer; 2014 Jul; 50(11):1855-63. PubMed ID: 24857781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
    Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K
    Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Skin signs associated with epidermal growth factor inhibitors].
    Hannoud S; Rixe O; Bloch J; Le Pelletier F; Lebrun-Vignes B; Doarika A; Khayat D; Chosidow O
    Ann Dermatol Venereol; 2006 Mar; 133(3):239-42. PubMed ID: 16800173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients.
    Jaka A; Gutiérrez-Rivera A; Ormaechea N; Blanco J; La Casta A; Sarasqueta C; Izeta A; Tuneu A
    Exp Dermatol; 2014 Oct; 23(10):751-3. PubMed ID: 25039761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.
    Luu M; Boone SL; Patel J; Sullivan P; Rademaker AW; Balagula Y; Lacouture ME
    Clin Exp Dermatol; 2011 Oct; 36(7):733-8. PubMed ID: 21689147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
    Rudin CM; Liu W; Desai A; Karrison T; Jiang X; Janisch L; Das S; Ramirez J; Poonkuzhali B; Schuetz E; Fackenthal DL; Chen P; Armstrong DK; Brahmer JR; Fleming GF; Vokes EE; Carducci MA; Ratain MJ
    J Clin Oncol; 2008 Mar; 26(7):1119-27. PubMed ID: 18309947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.
    Cignola S; Gonella S; Alessandra B; Palese A
    Eur J Oncol Nurs; 2016 Feb; 20():133-9. PubMed ID: 26187661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.